![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BioCryst’s Hereditary Angioedema Candidate Misses Primary Endpoints
BioCryst’s Hereditary Angioedema Candidate Misses Primary Endpoints
BioCryst’s avoralstat failed to meet primary endpoints in the OPuS-2 trial for hereditary angioedema, according to the company.
The company said statistically significant improvements were observed in the higher 500-mg dose for secondary endpoints, which measured quality of life, attack duration and attack severity.
Upcoming Events
-
21Oct